Vega Investment Solutions Makes New $611,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

Vega Investment Solutions acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 7,854 shares of the medical device company's stock, valued at approximately $611,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Private Trust Co. NA increased its position in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares during the last quarter. Optiver Holding B.V. purchased a new stake in shares of DexCom during the fourth quarter valued at approximately $33,000. TD Private Client Wealth LLC increased its position in shares of DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares during the last quarter. Larson Financial Group LLC increased its position in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC purchased a new stake in shares of DexCom during the fourth quarter valued at approximately $38,000. 97.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

DXCM has been the subject of a number of research analyst reports. Piper Sandler decreased their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Citigroup reaffirmed a "buy" rating and set a $102.00 price target (up from $82.00) on shares of DexCom in a research report on Thursday. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and raised their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Finally, Robert W. Baird decreased their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $98.00.

DexCom Price Performance

NASDAQ:DXCM opened at $84.83 on Friday. The firm has a market capitalization of $33.26 billion, a price-to-earnings ratio of 59.32, a P/E/G ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $129.97. The stock has a fifty day moving average of $73.26 and a 200 day moving average of $78.02. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. DexCom's quarterly revenue was up 12.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.32 EPS. On average, research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the sale, the executive vice president now owns 135,482 shares of the company's stock, valued at $10,002,636.06. The trade was a 4.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This trade represents a 4.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,926 shares of company stock valued at $4,734,384 over the last 90 days. Insiders own 0.32% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.